Fernandez Montes A, Martinez Lago N, De la Camara Gomez J, Covela Rua M, et al. FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic
colorectal cancer patients who converted to wild type RAS after receiving
first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX
trial. Ann Oncol 2019;30 Suppl 4:iv23-iv24.
PMID: 32085092